Over 40% Discontinue or Forget Treatment: It's Not Due to Weak Willpower — The Reality of Chronic Illness and the "Burden of Treatment"

Treating chronic diseases is more challenging to continue than to start. For long-term illnesses such as hypertension, diabetes, asthma, heart failure, and post-operative cancer treatment, the core of treatment involves consistently taking medication, not missing medical appointments, and accumulating tests and lifestyle improvements. However, in reality, this continuity quietly crumbles. A survey published in France in February 2026 revealed that 42% of patients undergoing long-term treatment had forgotten or interrupted their medication at least once in the past year. Experts have sounded the alarm because such lapses are not isolated incidents but occur across a broad spectrum of chronic disease care.

What is crucial here is not to dismiss this 42% figure as "laziness" or "lack of self-management." The survey indicated that much of the treatment discontinuation was not due to malicious refusal but was closer to "wear and tear" occurring in daily life. Forty percent of respondents felt that "treatment strongly dictates their day," and 39% felt there was a "discrepancy between what the medical side expects and what they can realistically continue" . In other words, the issue is not that patients do not follow orders, but that the treatment does not align with their lives.

Moreover, the period immediately after starting treatment is particularly fragile. The survey showed that 67% of people with less than a year of treatment history had experienced interruptions, significantly higher than those who had been in treatment for a longer time. During the period before habits are formed, when side effects, schedule disruptions, mood declines, and doubts about the significance of medication converge, treatment can easily fall out of daily routine. Patients may take newly prescribed medication diligently only for the first few weeks, then gradually increase the intervals. Alternatively, they may self-assess and decide to skip medication, thinking "I seem fine today." Such behavior is not a rare deviation but a risk embedded in the starting point of chronic disease treatment.

Another aspect that cannot be overlooked is the emotional burden patients carry. Reports indicate that many people feel "fatigue" from continuing long-term treatment, with about 70% of long-term treatment patients complaining of fatigue from "holding on," often compounded by guilt and anxiety. More than forgetting to take medication itself, self-denial such as "I failed again" or "I can't even adhere to such basic things" pushes patients into a corner. This makes it difficult to speak honestly with healthcare providers, causing them to miss the timing for consultation and ultimately leading to self-adjustment. Reports state that one in two patients adjusts their medication—reducing the dose, spacing it out, or taking breaks—without consulting healthcare providers.

This scenario aligns with the concept of "treatment burden" highlighted by another study in France. The ComPaRe study introduced by AP-HP showed that 38% of chronic disease patients felt their treatment burden was unacceptable in the long term. The factors that patients find distressing are not just the number of medications. They include the coordination of regular visits and tests, out-of-pocket expenses, the feeling of being reminded of their illness with each treatment, and the difficulty of relationships with healthcare providers, all contributing to the overall perception of treatment as burdensome. In France, where over 20 million people have chronic diseases, the accumulation of this burden naturally leads to the spread of treatment discontinuation.

In that sense, treatment discontinuation is not merely a "forgetting to take medication" issue. It is a problem of life design, a problem of the healthcare delivery system, and a problem of the relationship between patients and healthcare providers. The commentary compiled by VIDAL in March 2026 emphasizes the importance of focusing on patients' active "participation" rather than merely "observing" treatment. Based on the World Health Organization (WHO) definition, treatment continuation is not something patients unilaterally comply with but a process they engage in with understanding. If there is medication that should work but is not continued, the question should not be the patients' lack of willpower but whether the treatment is presented in a truly sustainable manner.

In reality, tools to support treatment are not sufficiently widespread. According to an OpinionWay survey, only 28% use tools equivalent to pill cases or pill organizers, 12% use reminders like smartphone alarms, and only 4% use dedicated apps. Despite the availability of technology, the majority of patients do not use it. Why? One reason is the strong demand for "simplifying the inherently complex and cumbersome treatment itself" rather than high-functioning support. In fact, 67% of patients with experience of forgetting to take medication answered that what is needed is "simpler and less burdensome treatment" rather than technology. Sustainability is prioritized over convenience.

Reactions on social media also focus on this point. In public share posts and surrounding articles, perceptions such as "If 42% forget, it's not individual negligence but a systemic issue," "It's harder to keep thinking about taking medication every day than taking it itself," and "The result that seniors are more regular was surprising" stand out. Particularly regarding the explanation of "simple oubli (simple forgetfulness)," the context strongly points to "saturation of life" as a result of overlapping work, housework, childcare, medical visits, and financial anxiety, rather than a mere memory issue. Headlines of public posts also highlighted that seniors are relatively more regular in continuing treatment, sharing the paradox that younger and working-age groups struggle more with balancing treatment and life.

This "generational reversal" is intriguing. Generally, chronic diseases and polypharmacy issues seem concentrated among the elderly. However, the current survey showed that treatment interruptions were more frequent among those under 35, who also tended to feel medication as a strong constraint. Irregular work, easily changing life rhythms, reduced sense of urgency when symptoms stabilize, and difficulty accepting illness as part of one's identity—when these conditions overlap, it becomes harder for younger individuals to "place treatment at the center of daily life." While medication management for the elderly is indeed a challenge, chronic disease management for the younger and working-age population needs to be addressed as an equally serious issue.

Furthermore, this issue does not only disadvantage the patients themselves. According to VIDAL's commentary, the cost that could be avoided by improving treatment adherence in Europe is estimated at 125 billion euros annually, with related excess mortality at a scale of 200,000 people per year. In France, non-adherence to chronic disease treatment is organized to lead to approximately 12,000 premature deaths annually, 100,000 avoidable hospitalizations, and a burden of about 9 billion euros annually for just the six major diseases. The inability to continue treatment not only worsens individual health but also rebounds on society as a whole through emergency visits, rehospitalizations, complications, and rising medical costs. To consider the sustainability of chronic disease healthcare, the focus should not only be on drug prices but also on whether the design prevents patient dropout.

So, what is needed? The answer is not simply to strengthen monitoring. Merely tracking whether medication has been taken does not resolve patient fatigue or confusion. What is needed is to specifically ask at the initial prescription stage, "What seems difficult to continue?" Is it anxiety about side effects, being too busy in the morning, medication clashing with work at noon, financial burden, or not wanting others to know about the illness? VIDAL organizes that the factors influencing treatment continuation span multiple dimensions, including individual patients, socioeconomic conditions, healthcare systems, disease characteristics, and treatment content. Thus, support must also be multifaceted.

At the core of that support is dialogue. French experts position treatment adherence not as a measure of how "obedient" patients are, but as an indicator reflecting the quality of the relationship between patients and healthcare providers. Is there an atmosphere where patients can easily say, "I haven't been taking it"? Can they talk about wanting to take a break from medication without being blamed? When they are anxious about not seeing effects, can they reaffirm the meaning of continuing treatment? If this is weak, even the best medication will end as a theoretical prescription. Conversely, if this is strong, patients are more likely to persevere even with somewhat complex treatments.

Treatment discontinuation for chronic diseases does not occur because patients are slacking off. It occurs because the difficulty of continuation is not yet sufficiently designed on the medical side. Prescribing medication and the medication actually continuing in the patient's life are separate issues. What this report and its reactions highlight is this obvious fact. The 42% figure should not be read as the percentage of patient failure but as a heavy warning that healthcare is still not organized around "ease of continuation."

Source URL

1. Le Figaro Santé
https://sante.lefigaro.fr/maladies-chroniques-trop-de-patients-decrochent-de-leur-traitement-selon-des-experts-20260309

2. OpinionWay Survey "Les Français et l’observance médicamenteuse"
42% experienced forgetting or interrupting medication in the past year, 40% feel treatment dictates their life, 39% feel a gap with medical expectations, more interruptions among younger people, higher interruption risk within the first year, usage rates of support tools, and other central data from this survey.
https://www.opinion-way.com/fr/publications/les-francais-et-lobservance-medicamenteuse-2026-22447/

3. Egora Article
Used to supplement the emotional and behavioral aspects of patients, such as fatigue, guilt, anxiety, and self-adjustment in long-term treatment patients, based on the OpinionWay survey content.
https://www.egora.fr/medical/actus-medicales/traitements-au-long-cours-4-patients-sur-10-ne-suivent-pas-correctement

4. AP-HP "ComPaRe Study" Introduction Page
Reference source for the fact that 38% of chronic disease patients feel their treatment burden is unacceptable in the long term, and that the burden is multifaceted, including costs, visits, tests, and relationships with healthcare providers, as well as the scale of people with chronic diseases in France.
https://www.aphp.fr/actualites/etude-compare-sur-le-fardeau-du-traitement-pres-de-40-des-patients-chroniques-estiment

5. VIDAL "Observance ou adhésion thérapeutique : où en est-on ?"
Used to organize the concept of treatment continuation as "patient's active involvement" rather than "patient's obedience," estimates of mortality, hospitalization, and economic losses in Europe and France, and the roles of doctors, pharmacists, and patient organizations.
https://www.vidal.fr/actualites/37500-observance-ou-adhesion-therapeutique-ou-en-est-on.html

6. Notre Temps Article & Public SNS Share Fragments
Referenced as supplementary material to confirm the general dissemination of the survey result "42% forget" and the perception that "seniors are relatively more regular."
https://www.notretemps.com/sante-bien-etre/medecine/traitements-comment-ameliorer-l-observance-des-patients-127881